Catabasis Pharmaceuticals, Inc. announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hotel in New York, NY.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hotel in New York, NY.
A webcast of the presentation will be available in the Investors section of the Company’s website, www.catabasis.com, and will be archived for 30 days following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 POLARIS DMD trial is expected to initiate in the second half of 2018. For more information on edasalonexent and our Phase 3 POLARIS DMD trial, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180808005022/en/
Contacts
Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
Source: Catabasis Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180808005022/en
